Onco-Innovations (STU:W1H) Notes Receivable: €0.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:W1H Onco-Innovations Ltd STU:W1H
12 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is Onco-Innovations Notes Receivable?

Onco-Innovations STU:W1H -2.79% 12 Notes Receivable is €0.00 Mil as of Apr. 2026. GuruFocus rates STU:W1H with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Onco-Innovations's Notes Receivable for the quarter that ended in Apr. 2026 was €0.00 Mil.

Onco-Innovations Notes Receivable Related Terms

Onco-Innovations Notes Receivable Historical Data

* Premium members only.

The historical data trend for Onco-Innovations's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onco-Innovations Notes Receivable Chart

Onco-Innovations Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Notes Receivable
0.00 0.00 0.00 0.00

Onco-Innovations Quarterly Data
Apr23 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:W1H
12GF Score
Onco-Innovations Ltd STU:W1H
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onco-Innovations Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Onco-Innovations (STU:W1H) has a Notes Receivable of €0.00 Mil as of Apr. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Onco-Innovations and its competitors.
Is Onco-Innovations' Notes Receivable too high?
Onco-Innovations' current Notes Receivable is €0.00 Mil. Overall, Onco-Innovations has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Onco-Innovations' Notes Receivable compare to VRTX and REGN?
Onco-Innovations' Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Onco-Innovations and its competitors. Onco-Innovations's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onco-Innovations stock overvalued right now?
Onco-Innovations (STU:W1H) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Onco-Innovations' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Onco-Innovations (STU:W1H), the current Notes Receivable is €0.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onco-Innovations Business Description

Other Exchanges ONCO:Canada
Address 7th Street South West, Suite 1039, Calgary, AB, CAN, T2R 1A5
Onco-Innovations Ltd is a pre-clinical stage biotechnology company working on developing drug candidates that can increase the effectiveness of current cancer treatments.
12GF Score

Get the complete analysis for STU:W1H

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price